PHI with Echinococcus multilocularis infection of liver
How does this condition affect your private health insurance?
Alveolar Echinococcosis of the liver is a rare but severe parasitic disease caused by the larval stage of the tapeworm Echinococcus multilocularis. Humans are accidental intermediate hosts, typically infected by ingesting parasite eggs from contaminated food, water, or direct contact with definitive hosts like foxes. The larvae primarily target the liver, forming aggressive, tumor-like infiltrations that grow slowly but invasively, destroying liver tissue. Untreated, it can metastasize to other organs, resembling a malignant tumor. Symptoms, such as abdominal pain, jaundice, and weight loss, often appear years after infection, indicating advanced disease. Diagnosis involves imaging, serology, and biopsy. Treatment is complex, usually involving prolonged anthelmintic therapy and often surgery.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Insidious onset, often asymptomatic for 5-15 years; once symptomatic, symptoms progress chronically over months to years.
Duration of Illness (Lifetime)
Chronic and progressive throughout life if untreated; requires lifelong antiparasitic medication and monitoring.
Cost of Treatment (Initial)
High (initial diagnosis, complex imaging, biopsy, prolonged antiparasitic medication, potential radical surgery).
Cost of Treatment (Lifetime)
Very high (lifelong medication, frequent monitoring, repeated imaging, potential multiple surgeries, liver transplantation in severe cases).
Mortality Rate
High (untreated mortality exceeds 90%; with treatment, significant mortality persists, especially if diagnosed late or if surgery is not feasible).
Risk of Secondary Damages
High (liver failure, biliary obstruction, portal hypertension, secondary bacterial infections, metastasis to lungs, brain, or bone).
Probability of Full Recovery
Low (complete eradication is rare without early, radical surgery; most patients require lifelong medical management to suppress the parasite and prevent progression).
Underlying Disease Risk
Low (Echinococcosis is a primary infection; however, immunosuppression is a known risk factor for developing more severe or disseminated disease).